Tue, 22 Sep 2026 07:07:26 GMT
Novo Nordisk Shares Tumble as Long-Term Revenue Targets Disappoint
Shares in Novo Nordisk plunged nearly 8% to close at 260 Danish kroner on Monday, hitting their lowest level since April after the Danish drugmaker's capital markets day presentation failed to reassure investors over its mid-term growth outlook. Despite showcasing positive Phase 3 trial data for its next-generation obesity and diabetes treatment Cagrisema, which achieved greater weight loss than Eli